Abstract:Brucellosis, a zoonotic disease caused by Brucella, presents a significant threat to both animal and human health. In animals, the disease can lead to infertility, miscarriage, and high fever, while in humans, symptoms may include recurrent fever, fatigue, sweating, hepatosplenomegaly, and joint and muscle pain following infection. Treatment often involves long-term antibiotic therapy, placing a substantial psychological and financial burden on patients. While vaccination is crucial for prevention, current animal vaccines have drawbacks such as residual virulence, and a safe and effective human vaccine is lacking. Hence, the development of a vaccine for brucellosis is imperative. In this study, we utilized bioinformatics methods to design a multi-epitope vaccine targeting Brucella. Targeting Heme transporter BhuA and polysaccharide export protein, we identified antigenic epitopes, including six cytotoxic T lymphocyte (CTL) dominant epitopes, six helper T lymphocyte (HTL) dominant epitopes, one conformation B cell dominant epitope, and three linear B cell dominant epitopes. By linking these epitopes with appropriate linkers and incorporating a Toll-like receptor (TLR) agonist (human beta-defensin-2) and an auxiliary peptide (Pan HLA-DR epitopes), we constructed the multi-epitope vaccine (MEV). The MEV demonstrated high antigenicity, non-toxicity, non-allergenicity, non-human homology, stability, and solubility. Molecular docking analysis and molecular dynamics simulations confirmed the interaction and stability of the MEV with receptors (MHCI, MHCII, TLR4). Codon optimization and in silico cloning validated the translation efficiency and successful expression of MEV in Escherichia coli. Immunological simulations further demonstrated the efficacy of MEV in inducing robust immune responses. In conclusion, our findings suggest that the engineered MEVs have the potential to stimulate both humoral and cellular immune responses, offering valuable insights for the future development of safe and efficient Brucella vaccines.

Construction and Identification of Eukaryotic Expression Vector for WbkC Gene of Brucella Melitensis

Constructing Prokaryotic Vector of BC047440 Gene Expression and Purification of Its Recombinant Protein

Construction of a low molecular weight plasmid vector for the capture of genes encoding exported proteins.

Construction of Eukaryotic Expression System of Staphylococcal Enterotoxin B Gene and Identification of Goal Protein

Construction and Application of the Vectors to Identify Genes Encoding Exported Proteins of Escherichia Coli.

Development of an inducible secretory expression system in Bacillus licheniformis based on an engineered xylose operon.

Construction and Identification of a Recombinant Attenuated Salmonella Expressing Streptococcus suis sly Gene

The Construction and Sub-Cellular Localization Analysis of Novel Mycobacterial Membrane-Anchored Expression Vector

Establishment of PCR for Detecting Bovine Brucella

Construction of multiple antigenic peptide and the immunity analysis

Construction and Evaluation of the Brucella Double Gene Knock-out Vaccine Strain MB6 Δbp26ΔwboA (RM6)

Construction and Identification of Bait Expression Plasmid pGBKT7-EBP50 in Yeast Two-hybrid System

[Construction and Expression of Prokaryotic Vector of Single Chain Antibody Derived from a New Clone of Anti-Cd14 Antibody ZCH-7-2F9].

Immunoproteomic analysis of Brucella melitensis and identification of a new immunogenic candidate protein for the development of brucellosis subunit vaccine

Conservation of seven genes involved in the biosynthesis of the lipopolysaccharide O-side chain in Brucella spp

Lable-free based comparative proteomic analysis of secretory proteins of rough Brucella mutants.

Calibration of doxycycline for use in urinary tract infections with enterococci.

Development of a novel multi-epitope vaccine for brucellosis prevention

Strain-level Identification of Brucella Melitensis Reference Strain 63/9 Using Multiplex PCR Method by Targeting BMEA_B0162 and BMEA_A1238

Design of a multi-epitope vaccine candidate against Brucella melitensis

New synthesis of oligosaccharides modelling the M epitope of the Brucella O-polysaccharide